Menu Search
Equities

Maravai LifeSciences Holdings Inc

MRVI*:MEX

Maravai LifeSciences Holdings Inc

Actions
  • Price (MXN)180.25
  • Today's Change28.35 / 18.66%
  • Shares traded--
  • 1 Year change-8.88%
  • Beta--
Data delayed at least 20 minutes, as of Nov 28 2023 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.

  • Revenue in USD (TTM)274.10m
  • Net income in USD-131.04m
  • Incorporated2014
  • Employees570.00
  • Location
    Maravai LifeSciences Holdings Inc10770 Wateridge Circle Suite 200Suite 200SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 546-0004
  • Fax+1 (302) 655-5049
  • Websitehttps://www.maravai.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.